Cervical Cancer (Human Papillomavirus - HPV)
Overview
Plain-Language Overview
Cervical Cancer (Human Papillomavirus - HPV) is a type of cancer that affects the cervix, which is the lower part of the uterus connecting to the vagina. It is primarily caused by persistent infection with high-risk types of HPV, a common sexually transmitted virus. This cancer develops slowly over time, often starting with abnormal cell changes that can be detected early. If untreated, these changes can progress to invasive cancer, which may cause symptoms like abnormal vaginal bleeding or pelvic pain. The disease mainly impacts the female reproductive system and can affect overall health by spreading to nearby tissues or distant organs. Early detection through screening is crucial because it allows treatment before cancer becomes advanced. Understanding the role of HPV infection is key to preventing and managing this condition.
Clinical Definition
Cervical Cancer (Human Papillomavirus - HPV) is a malignant neoplasm arising from the epithelial cells of the cervix, predominantly caused by persistent infection with high-risk oncogenic types of HPV, especially types 16 and 18. The pathogenesis involves integration of viral DNA into host cells, leading to overexpression of viral oncoproteins E6 and E7, which inactivate tumor suppressors p53 and Rb, respectively, resulting in uncontrolled cellular proliferation. The disease typically progresses from cervical intraepithelial neoplasia (CIN) to invasive carcinoma over years. Clinically, it is significant due to its potential for local invasion and metastasis, causing morbidity and mortality worldwide. The most common histologic types are squamous cell carcinoma and adenocarcinoma. Screening programs using Pap smears and HPV DNA testing have reduced incidence and mortality by detecting precancerous lesions early. Understanding the molecular mechanisms and natural history of HPV-related cervical carcinogenesis is essential for diagnosis and management.
Inciting Event
Infection with high-risk HPV strains is the initiating event for cervical carcinogenesis.
Acquisition of HPV occurs through sexual contact with an infected partner.
Latency Period
The latency period from initial HPV infection to invasive cervical cancer can be 10-20 years.
Progression from low-grade CIN to high-grade CIN and invasive cancer typically spans several years.
Diagnostic Delay
Lack of regular Pap smear screening leads to delayed detection of precancerous changes.
Early cervical cancer is often asymptomatic, causing patients to present late.
Misattribution of symptoms like postcoital bleeding to benign causes delays diagnosis.
Clinical Presentation
Signs & Symptoms
Postcoital bleeding is the most common presenting symptom
Intermenstrual or irregular vaginal bleeding often occurs
Watery, bloody vaginal discharge may be present
Pelvic pain or dyspareunia in advanced disease
Urinary symptoms such as frequency or obstruction if the tumor invades adjacent structures
History of Present Illness
Initial symptoms include intermittent postcoital bleeding and vaginal discharge.
Progression leads to irregular menstrual bleeding and pelvic pain.
Advanced disease may present with urinary symptoms or leg edema due to local invasion.
Past Medical History
History of persistent high-risk HPV infection or previous CIN lesions increases risk.
Prior immunosuppressive conditions such as HIV infection worsen prognosis.
Lack of HPV vaccination is a modifiable risk factor.
Family History
No strong familial inheritance pattern, but family history of cervical cancer may indicate shared environmental or behavioral risk factors.
Rarely, genetic predispositions affecting immune response to HPV may contribute.
Physical Exam Findings
Friable cervical lesions with irregular, exophytic, or ulcerative appearance on speculum exam
Cervical bleeding or contact bleeding upon examination
Enlarged, firm pelvic lymph nodes may be palpable in advanced disease
Parametrial induration or fixation indicating local invasion
Pelvic mass or irregular cervical contour on bimanual exam
Diagnostic Workup
Diagnostic Criteria
Diagnosis of cervical cancer is established through a combination of cytologic screening (Pap smear) showing abnormal epithelial cells and confirmatory colposcopic biopsy demonstrating invasive carcinoma. High-risk HPV DNA testing supports the diagnosis by identifying oncogenic viral types. Histopathologic examination reveals malignant epithelial cells with features such as nuclear atypia, increased mitotic figures, and stromal invasion. Imaging studies may be used to assess local extent and metastasis but are not diagnostic. Definitive diagnosis requires tissue confirmation of invasive cancer.
Pathophysiology
Key Mechanisms
Persistent infection with high-risk HPV types 16 and 18 leads to expression of viral oncoproteins E6 and E7, which inactivate tumor suppressors p53 and Rb.
E6-mediated degradation of p53 impairs apoptosis and DNA repair, promoting genomic instability.
E7-mediated inactivation of Rb releases E2F transcription factors, driving uncontrolled cell cycle progression.
Integration of HPV DNA into host genome disrupts normal cell regulation and promotes malignant transformation.
Chronic inflammation and immune evasion by HPV contribute to progression from cervical intraepithelial neoplasia (CIN) to invasive carcinoma.
| Involvement | Details |
|---|---|
| Organs | Cervix is the primary organ affected by HPV-induced malignant transformation leading to cervical cancer. |
Lymph nodes serve as common sites for regional metastasis and are important in staging. | |
Uterus may be involved in advanced disease with local extension of cervical cancer. | |
| Tissues | Cervical epithelium undergoes dysplastic changes progressing to invasive carcinoma in cervical cancer. |
Basement membrane integrity loss allows invasion of malignant cells into underlying stroma. | |
Lymphatic tissue adjacent to the cervix is a common site for early metastatic spread. | |
| Cells | Squamous epithelial cells of the cervix are the primary site of malignant transformation in cervical cancer. |
Langerhans cells participate in antigen presentation and immune response to HPV infection. | |
T lymphocytes mediate immune surveillance and cytotoxic response against HPV-infected and transformed cells. | |
| Chemical Mediators | E6 and E7 oncoproteins from high-risk HPV types inactivate tumor suppressors p53 and Rb, driving carcinogenesis. |
Vascular endothelial growth factor (VEGF) promotes angiogenesis essential for tumor growth and metastasis. | |
Cytokines such as IL-6 and TNF-alpha contribute to the inflammatory microenvironment supporting tumor progression. |
Treatments
Pharmacological Treatments
Cisplatin
- Mechanism:
Forms DNA crosslinks causing apoptosis in rapidly dividing cancer cells.
- Side effects:
Nephrotoxicity
Ototoxicity
Peripheral neuropathy
Myelosuppression
- Clinical role:
First-line
Paclitaxel
- Mechanism:
Stabilizes microtubules and inhibits mitosis leading to cancer cell death.
- Side effects:
Peripheral neuropathy
Myelosuppression
Hypersensitivity reactions
- Clinical role:
First-line
Bevacizumab
- Mechanism:
Monoclonal antibody that inhibits VEGF, reducing tumor angiogenesis.
- Side effects:
Hypertension
Proteinuria
Thromboembolism
Delayed wound healing
- Clinical role:
Adjunctive
Topotecan
- Mechanism:
Inhibits topoisomerase I, causing DNA damage and apoptosis in cancer cells.
- Side effects:
Myelosuppression
Nausea
Fatigue
- Clinical role:
Second-line
Non-pharmacological Treatments
Surgical excision such as radical hysterectomy for early-stage cervical cancer.
Radiation therapy including external beam and brachytherapy for local tumor control.
Regular cervical cancer screening with Pap smear and HPV DNA testing for early detection.
HPV vaccination to prevent infection with high-risk HPV types causing cervical cancer.
Prevention
Pharmacological Prevention
Prophylactic HPV vaccination with bivalent, quadrivalent, or nonavalent vaccines targeting high-risk HPV types
Topical immune modulators are under investigation but not standard
No effective pharmacologic agents exist for established cervical dysplasia prevention
Non-pharmacological Prevention
Regular cervical cancer screening with Pap smear and HPV testing starting at age 21
Safe sexual practices including condom use to reduce HPV transmission
Smoking cessation to decrease cofactor risk
Early treatment of cervical intraepithelial neoplasia (CIN) to prevent progression
Public health education to increase HPV vaccine uptake and screening adherence
Outcome & Complications
Complications
Local invasion causing ureteral obstruction and hydronephrosis
Pelvic fistulas between the bladder, rectum, or vagina
Distant metastases to lungs, liver, or bone
Severe anemia from chronic bleeding
Infection and sepsis secondary to necrotic tumor tissue
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Cervical Cancer (Human Papillomavirus - HPV) versus Cervicitis
Cervical Cancer (Human Papillomavirus - HPV) | Cervicitis |
|---|---|
Persistent high-risk HPV infection with history of multiple sexual partners | Recent unprotected sexual intercourse with new or multiple partners |
Chronic progressive cervical epithelial changes leading to dysplasia and invasive carcinoma | Acute onset with mucopurulent cervical discharge and cervical friability |
Positive cervical biopsy showing squamous cell carcinoma with HPV DNA integration | Positive cervical swab culture for Chlamydia trachomatis or Neisseria gonorrhoeae |
Cervical Cancer (Human Papillomavirus - HPV) versus Endometrial carcinoma
Cervical Cancer (Human Papillomavirus - HPV) | Endometrial carcinoma |
|---|---|
Often affects women aged 30-50 years with persistent HPV infection | Typically postmenopausal women aged >55 years |
Pelvic imaging reveals cervical mass or irregular cervical contour | Ultrasound shows thickened endometrial stripe without cervical mass |
Squamous cell carcinoma or adenocarcinoma arising from cervical epithelium with HPV-related changes | Endometrioid adenocarcinoma arising from endometrial glands |
Cervical Cancer (Human Papillomavirus - HPV) versus Vaginal cancer
Cervical Cancer (Human Papillomavirus - HPV) | Vaginal cancer |
|---|---|
Persistent high-risk HPV infection primarily involving the cervix | History of prior pelvic radiation or vaginal intraepithelial neoplasia |
Tumor arises from cervical squamous or glandular epithelium with HPV oncogene expression | Tumor arises from vaginal squamous epithelium with possible HPV association |
Mass centered in the cervix with possible extension to adjacent structures | Mass localized to vaginal wall without cervical involvement |
Cervical Cancer (Human Papillomavirus - HPV) versus Benign cervical polyp
Cervical Cancer (Human Papillomavirus - HPV) | Benign cervical polyp |
|---|---|
Persistent abnormal vaginal bleeding with progressive cervical lesion | Intermittent spotting or postcoital bleeding without progressive symptoms |
Malignant squamous or glandular epithelial cells with dysplasia and invasion | Polyp composed of benign endocervical glandular and stromal tissue |
Histology shows high-grade dysplasia and HPV DNA integration | Histology shows no cellular atypia or HPV-related changes |
Cervical Cancer (Human Papillomavirus - HPV) versus Pelvic inflammatory disease (PID)
Cervical Cancer (Human Papillomavirus - HPV) | Pelvic inflammatory disease (PID) |
|---|---|
Chronic high-risk HPV infection without acute STI symptoms | Recent sexually transmitted infection with Neisseria gonorrhoeae or Chlamydia trachomatis |
Often asymptomatic or presents with abnormal vaginal bleeding and cervical lesion | Acute pelvic pain, fever, and cervical motion tenderness |
Normal inflammatory markers with positive HPV DNA testing and abnormal Pap smear | Elevated inflammatory markers and positive cervical swabs for bacterial pathogens |